Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 24, 2006, Pages 6165-6169

  Bell, Ian M ^a   Bednar, Rodney A ^a   Fay, John F ^a   Gallicchio, Steven N ^a   Hochman, Jerome H ^a   McMasters, Daniel R ^a   Miller Stein, Cynthia ^a   Moore, Eric L ^a   Mosser, Scott D ^a   Pudvah, Nicole T ^a   Quigley, Amy G ^a   Salvatore, Christopher A ^a   Stump, Craig A ^a   Theberge, Cory R ^a   Wong, Bradley K ^a   Zartman, C Blair ^a   Zhang, Xu Fang ^a   Kane, Stefanie A ^a   Graham, Samuel L ^a   Vacca, Joseph P ^a   Williams, Theresa M ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CGRP; CGRP receptor antagonists; Migraine; Spirohydantoin

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; SPIROMUSTINE;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG IDENTIFICATION; DRUG PENETRATION; DRUG POTENCY; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT; NANOPARTICLE; NONHUMAN; PROCESS OPTIMIZATION; SURFACE PROPERTY;

ADMINISTRATION, ORAL; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; CELL LINE; HUMANS; HYDANTOINS; KIDNEY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33750704948     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.09.045     Document Type: Article

References (15)

1. Goadsby P.J., Lipton R.B., and Ferrari M.D. N. Eng. J. Med. 346 (2002) 257
2. Edvinsson L. Pharmacol. Toxicol. 89 (2001) 65
3. Goadsby P.J. Drugs 65 (2005) 2557
4. Olesen J., Diener H.-C., Husstedt I.W., Goadsby P.J., Hall D., Meier U., Pollentier S., and Lesko L.M. N. Eng. J. Med. 350 (2004) 1104
5. Iovino M., Feifel U., Yong C.-L., Wolters J.-M., and Wallenstein G. Cephalalgia 24 (2004) 645
6. Williams T.M., Stump C.A., Nguyen D.N., Quigley A.G., Bell I.M., Gallicchio S.N., Zartman C.B., Wan B.-L., Della Penna K., Kunapuli P., Kane S.A., Koblan K.S., Mosser S.D., Rutledge R.Z., Salvatore C., Fay J.F., Vacca J.P., and Graham S.L. Bioorg. Med. Chem. Lett. 16 (2006) 2595
7. Burgey C.S., Stump C.A., Nguyen D.N., Deng J.Z., Quigley A.G., Norton B.R., Bell I.M., Mosser S.D., Salvatore C.A., Rutledge R.Z., Kane S.A., Koblan K.S., Vacca J.P., Graham S.L., and Williams T.M. Bioorg. Med. Chem. Lett. 16 (2006) 5052
8. Bell, I. M.; Stump, C. A. WO 2006/029153.
9. In related analogues, methylation of the imide nitrogen of the spirohydantoin led to a significant loss of potency (data not shown).
10. Clark D.E. J. Pharm. Sci. 88 (1999) 807
11. Prueksaritanont T., Meng Y., Ma B., Leppert P., Hochman J., Tang C., Perkins J., Zrada M., Meissner R., Duggan M.E., and Lin J.H. Xenobiotica 32 (2002) 207
12. Sun D., Yu L.X., Hussain M.A., Wall D.A., Smith R.L., and Amidon G.L. Curr. Opin. Drug Discov. Devel. 7 (2004) 75
13. Martinez M.N., and Amidon G.L. J. Clin. Pharmacol. 42 (2002) 620
14. 1H NMR, HPLC, and HRMS. Additional synthetic details are provided in: Bell, I. M.; Gallicchio, S. N.; Theberge, C. R.; Zhang, X.-F.; Stump, C.; Zartman, C. B. WO 2004/082605.
15. Absolute stereochemistry established by X-ray crystallography on a derivative of the corresponding aniline.